The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Zuzanna Urban‐WójciukInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, PolandMohd M. KhanLaboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United StatesBenjamin L. OylerUniversity of Maryland School of Medicine, Baltimore, MD, United StatesRobin FåhræusDepartment of Medical Biosciences, Umeå University, Umeå, SwedenNatalia Marek-TrzonkowskaInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, PolandAleksandra Nita‐LazarLaboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United StatesTed R. HuppCell Signaling Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United KingdomDavid R. GoodlettDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, United States
2019en
ABI
Abstract
In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.
Identifiers
Citations and references
Cited by 20 references